Contineum Therapeutics, Inc.
NMS: CTNMLive Quote
📈 ZcoreAI Score
Our AI model analyzes Contineum Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get CTNM Z-Score →About Contineum Therapeutics, Inc.
Healthcare
Biotechnology
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
📊 Fundamental Analysis
Contineum Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -26.1%, which indicates that capital utilization is currently under pressure.
At a current price of $12.87, CTNM currently sits at the 73rd percentile of its 52-week range (Range: $3.35 - $16.33).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$480.51M
Trailing P/E
--
Forward P/E
-5.92
Beta (5Y)
1.39
52W High
$16.33
52W Low
$3.35
Avg Volume
278K
Day High
Day Low